Table 2: Baseline characteristics of 15 dogs diagnosed with splenic hemangiosarcoma randomized to one of three doses of I’m-Yunity.

I'm-Yunity (polysaccharopeptide)
25 mg/kg/day50 mg/kg/day100 mg/kg/day
( 𝑛 = 5 )( 𝑛 = 5 )( 𝑛 = 5 )

Breed1 mixed breed (20%)2 mixed breed (40%)2 mixed breed (40%)

4 pure breed (80%)

3 pure breed (60%)

3 pure breed (60%)
Age (years)9.0 ± 1.99.6 ± 2.78.6 ± 1.1
Weight (kg)34.0 ± 7.028.2 ± 4.830.0 ± 12.8
Sex1 female (20%)2 female (40%)1 female (20%)
4 male (80%)3 male (60%)4 male (80%)
Metastatic disease present at enrollment2 no (40%)2 no (40%)2 no (40%)
3 yes (60%)3 yes (60%)3 yes (60%)
Time from diagnosis to study enrollment (days)16 ± 923 ± 1020 ± 8